|Part of a series on|
The adenosine receptors (or P1 receptors) are a class of purinergic G protein-coupled receptors with adenosine as the endogenous ligand. There are four known types of adenosine receptors in humans: A1, A2A, A2B and A3; each is encoded by a different gene.
Each type of adenosine receptor has different functions, although with some overlap. For instance, both A1 receptors and A2A play roles in the heart, regulating myocardial oxygen consumption and coronary blood flow, while the A2A receptor also has broader anti-inflammatory effects throughout the body. These two receptors also have important roles in the brain, regulating the release of other neurotransmitters such as dopamine and glutamate, while the A2B and A3 receptors are located mainly peripherally and are involved in processes such as inflammation and immune responses.
Most older compounds acting on adenosine receptors are nonselective, with the endogenous agonist adenosine being used in hospitals as treatment for severe tachycardia (rapid heart beat), and acting directly to slow the heart through action on all four adenosine receptors in heart tissue, as well as producing a sedative effect through action on A1 and A2A receptors in the brain. Xanthine derivatives such as caffeine and theophylline act as non-selective antagonists at A1 and A2A receptors in both heart and brain and so have the opposite effect to adenosine, producing a stimulant effect and rapid heart rate. These compounds also act as phosphodiesterase inhibitors, which produces additional anti-inflammatory effects, and makes them medically useful for the treatment of conditions such as asthma, but less suitable for use in scientific research.
Newer adenosine receptor agonists and antagonists are much more potent and subtype-selective, and have allowed extensive research into the effects of blocking or stimulating the individual adenosine receptor subtypes, which is now resulting in a new generation of more selective drugs with many potential medical uses. Some of these compounds are still derived from adenosine or from the xanthine family, but researchers in this area have also discovered many selective adenosine receptor ligands that are entirely structurally distinct, giving a wide range of possible directions for future research.
|A1||ADORA1||Gi/o → cAMP↑/↓
|A2A||ADORA2A||Gs → cAMP↑|
|A2B||ADORA2B||Gs → cAMP↑
Also recently discovered A2B has Gq → DAG and IP3 → Release calcium → activate calmodulin → activate myosin light chain kinase → phosphorylate myosin light chain → myosin light chain plus actin → bronchoconstriction
|A3||ADORA3||Gi/o → ↓cAMP|
A1 adenosine receptor
The adenosine A1 receptor has been found to be ubiquitous throughout the entire body.
This receptor has an inhibitory function on most of the tissues in which it is expressed. In the brain, it slows metabolic activity by a combination of actions. Presynaptically, it reduces synaptic vesicle release while post synaptically it has been found to stabilize the magnesium on the NMDA receptor.
Antagonism and agonism
Specific A1 antagonists include 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX), and Cyclopentyltheophylline (CPT) or 8-cyclopentyl-1,3-dipropylxanthine (CPX), while specific agonists include 2-chloro-N(6)-cyclopentyladenosine (CCPA).
In the heart
The A1, together with A2A receptors of endogenous adenosine play a role in regulating myocardial oxygen consumption and coronary blood flow. Stimulation of the A1 receptor has a myocardial depressant effect by decreasing the conduction of electrical impulses and suppressing pacemaker cell function, resulting in a decrease in heart rate. This makes adenosine a useful medication for treating and diagnosing tachyarrhythmias, or excessively fast heart rates. This effect on the A1 receptor also explains why there is a brief moment of cardiac standstill when adenosine is administered as a rapid IV push during cardiac resuscitation. The rapid infusion causes a momentary myocardial stunning effect.
In normal physiological states, this serves as a protective mechanism. However, in altered cardiac function, such as hypoperfusion caused by hypotension, heart attack or cardiac arrest caused by nonperfusing bradycardias, adenosine has a negative effect on physiological functioning by preventing necessary compensatory increases in heart rate and blood pressure that attempt to maintain cerebral perfusion.
In neonatal medicine
Adenosine antagonists are widely used in neonatal medicine;
A reduction in A1 expression appears to prevent hypoxia-induced ventriculomegaly and loss of white matter, which raises the possibility that pharmacological blockade of A1 may have clinical utility.
Theophylline and caffeine are nonselective adenosine antagonists that are used to stimulate respiration in premature infants.
Adenosine receptors play a key role in the homeostasis of bone. The A1 receptor has been shown to stimulate osteoclast differentiation and function. Studies have found that blockade of the A1 Receptor suppresses the osteoclast function, leading to increased bone density.
A2A adenosine receptor
As with the A1, the A2A receptors are believed to play a role in regulating myocardial oxygen consumption and coronary blood flow.
The activity of A2A adenosine receptor, a G-protein coupled receptor family member, is mediated by G proteins that activate adenylyl cyclase. It is abundant in basal ganglia, vasculature and platelets and it is a major target of caffeine.
The A2A receptor is responsible for regulating myocardial blood flow by vasodilating the coronary arteries, which increases blood flow to the myocardium, but may lead to hypotension. Just as in A1 receptors, this normally serves as a protective mechanism, but may be destructive in altered cardiac function.
Agonists and antagonists
The role of A2A receptor opposes that of A1 in that it inhibits osteoclast differentiation and activates osteoblasts. Studies have shown it to be effective in decreasing inflammatory osteolysis in inflamed bone. This role could potentiate new therapeutic treatment in aid of bone regeneration and increasing bone volume.
A2B adenosine receptor
This integral membrane protein stimulates adenylate cyclase activity in the presence of adenosine. This protein also interacts with netrin-1, which is involved in axon elongation.
Similarly to A2A receptor, the A2B receptor promotes osteoblast differentiation. The osteoblast cell is derived from the Mesenchymal Stem Cell (MSC) which can also differentiate into a chondrocyte. The cell signalling involved in the stimulation of the A2B receptor directs the route of differentiation to osteoblast, rather than chondrocyte via the Runx2 gene expression. Potential therapeutic application in aiding bone degenerative diseases, age related changes as well as injury repair.
A3 adenosine receptor
It has been shown in studies to inhibit some specific signal pathways of adenosine. It allows for the inhibition of growth in human melanoma cells. Specific antagonists include MRS1191, MRS1523 and MRE3008F20, while specific agonists include Cl-IB-MECA and MRS3558.
The role of A3 receptor is less defined in this field. Studies have shown that it plays a role in the downregulation of osteoclasts. Its function in regards to osteoblasts remains ambiguous.
- Fredholm BB, Abbracchio MP, Burnstock G, Dubyak GR, Harden TK, Jacobson KA, Schwabe U, Williams M (1997). "Towards a revised nomenclature for P1 and P2 receptors". Trends Pharmacol. Sci. 18 (3): 79–82. doi:10.1016/S0165-6147(96)01038-3. PMC 4460977. PMID 9133776.
- Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001). "International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors". Pharmacol. Rev. 53 (4): 527–52. PMID 11734617.
- Gao ZG, Jacobson KA (September 2007). "Emerging adenosine receptor agonists". Expert Opinion on Emerging Drugs. 12 (3): 479–92. doi:10.1517/14728184.108.40.2069. PMID 17874974.
- Haskó G, Pacher P (March 2008). "A2A receptors in inflammation and injury: lessons learned from transgenic animals". Journal of Leukocyte Biology. 83 (3): 447–55. doi:10.1189/jlb.0607359. PMC 2268631. PMID 18160539.
- Kalda A, Yu L, Oztas E, Chen JF (October 2006). "Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease". Journal of the Neurological Sciences. 248 (1–2): 9–15. doi:10.1016/j.jns.2006.05.003. PMID 16806272.
- Fuxe K, Ferré S, Genedani S, Franco R, Agnati LF (September 2007). "Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function". Physiology & Behavior. 92 (1–2): 210–7. doi:10.1016/j.physbeh.2007.05.034. PMID 17572452.
- Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S (December 2007). "Adenosine A2A receptors and basal ganglia physiology". Progress in Neurobiology. 83 (5): 277–92. doi:10.1016/j.pneurobio.2007.05.001. PMC 2148496. PMID 17646043.
- Cunha RA, Ferré S, Vaugeois JM, Chen JF (2008). "Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders". Current Pharmaceutical Design. 14 (15): 1512–24. doi:10.2174/138161208784480090. PMC 2423946. PMID 18537674.
- Peart JN, Headrick JP (May 2007). "Adenosinergic cardioprotection: multiple receptors, multiple pathways". Pharmacology & Therapeutics. 114 (2): 208–21. doi:10.1016/j.pharmthera.2007.02.004. PMID 17408751.
- Cohen MV, Downey JM (May 2008). "Adenosine: trigger and mediator of cardioprotection". Basic Research in Cardiology. 103 (3): 203–15. doi:10.1007/s00395-007-0687-7. PMID 17999026.
- Ferré S (May 2008). "An update on the mechanisms of the psychostimulant effects of caffeine". Journal of Neurochemistry. 105 (4): 1067–79. doi:10.1111/j.1471-4159.2007.05196.x. PMID 18088379.
- Osadchii OE (June 2007). "Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease". Cardiovascular Drugs and Therapy. 21 (3): 171–94. doi:10.1007/s10557-007-6014-6. PMID 17373584.
- Baraldi PG, Tabrizi MA, Gessi S, Borea PA (January 2008). "Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility". Chemical Reviews. 108 (1): 238–63. doi:10.1021/cr0682195. PMID 18181659.
- Cristalli G, Lambertucci C, Marucci G, Volpini R, Dal Ben D (2008). "A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists". Current Pharmaceutical Design. 14 (15): 1525–52. doi:10.2174/138161208784480081. PMID 18537675.
- Unless else specified in boxes, then ref is:senselab Archived 2009-02-28 at the Wayback Machine
- Kara FM, Doty SB, Boskey A, Goldring S.. (2010). Adenosine A1 Receptors (A1R) Regulate Bone Resorption II Adenosine A1R Blockade or Deletion Increases Bone Density and Prevents Ovariectomy-Induced Bone Loss. Arthritis Rheumatology . 62 (2), 534–541.
- He W, Wilder T, Cronstein BN (2013). "Rolofylline, an adenosine A1 receptor antagonist, inhibits osteoclast differentiation as an inverse agonist". Br J Pharmacol. 170 (6): 1167–1176. doi:10.1111/bph.12342. PMC 3838692.
- "Entrez Gene: ADORA2A adenosine A2A receptor".
- Jacobson KA, Gao ZG (2006). "Adenosine receptors as therapeutic targets". Nature Reviews. Drug Discovery. 5 (3): 247–64. doi:10.1038/nrd1983. PMC 3463109. PMID 16518376.
- Mediero A, Frenkel SR, Wilder T, HeW MA, Cronstein BN (2012). "Adenosine A2A receptor activation prevents wearparticle-induced osteolysis". Sci Transl Med. 4 (135): 135–165.
- Mediero A, Kara FM, Wilder T, Cronstein BN (2012). "Adenosine A 2A receptor ligation inhibits osteoclast formation". Am J Pathol. 180 (2): 775–786. doi:10.1016/j.ajpath.2011.10.017. PMC 3349861.
- Costa MA, Barbosa A, Neto E, Sá-e-Sousa A, Freitas R, Neves JM, Magalhães-Cardoso T, Ferreirinha F, Correia-de-Sá P (2011). "On the role of subtype selective adenosine receptor agonists during proliferation and osteogenic differentiation of human primary bone marrow stromal cells". J Cell Physiol. 226 (5): 1353–1366. doi:10.1002/jcp.22458.
- Carroll SH, Ravid K (2013). "Differentiation of mesenchymal stem cells to osteoblasts and chondrocytes: a focus on adenosine receptors". Expert Reviews in Molecular Medicine. 15. doi:10.1017/erm.2013.2.
- Rath-Wolfson L, Bar-Yehuda S, Madi L, Ochaion A, Cohen S, Zabutti A, Fishman P (2006). "IB-MECA, an A". Clin Exp Rheumatol. 24: 400–406.